SCAR20 Gene

SCAR20 — IQCA1 (IQ Motif Containing A)

<div class="infobox infobox-gene">
<div class="infobox-header">SCAR20</div>
<div class="infobox-row"><strong>Full Name:</strong> Severe Congenital Autosomal Recessive 20 / IQ Motif Containing A</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 11q13.2</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> [65250](https://www.ncbi.nlm.nih.gov/gene/65250)</div>
<div class="infobox-row"><strong>OMIM:</strong> [616151](https://www.omim.org/entry/616151)</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000165704</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q96MC7</div>
<div class="infobox-row"><strong>Protein Name:</strong> IQCA1 (IQ Motif Containing A)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> SCAR20 Syndrome (Autosomal Recessive Sensorineural Hearing Loss with Developmental Delay), Coffin-Lowry Syndrome-like Phenotype</div>
</div>

Summary

SCAR20 — IQCA1 (IQ Motif Containing A)

<div class="infobox infobox-gene">
<div class="infobox-header">SCAR20</div>
<div class="infobox-row"><strong>Full Name:</strong> Severe Congenital Autosomal Recessive 20 / IQ Motif Containing A</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 11q13.2</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> [65250](https://www.ncbi.nlm.nih.gov/gene/65250)</div>
<div class="infobox-row"><strong>OMIM:</strong> [616151](https://www.omim.org/entry/616151)</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000165704</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q96MC7</div>
<div class="infobox-row"><strong>Protein Name:</strong> IQCA1 (IQ Motif Containing A)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> SCAR20 Syndrome (Autosomal Recessive Sensorineural Hearing Loss with Developmental Delay), Coffin-Lowry Syndrome-like Phenotype</div>
</div>

Summary

SCAR20 (Severe Congenital Autosomal Recessive 20), also known as IQCA1 (IQ Motif Containing A), is a gene whose mutations cause a severe autosomal recessive neurodevelopmental disorder characterized by profound sensorineural hearing loss present from birth, distinctive facial dysmorphism, and global developmental delay [1]. The protein is ubiquitously expressed with high expression in the brain, particularly in the cerebral [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus), where it localizes primarily to the nucleus and is involved in transcriptional regulation and ribosomal biogenesis [2].

The discovery of SCAR20 as the causative gene for this syndrome provided important insights into the molecular pathways required for normal hearing development and cognitive function. The protein contains multiple protein interaction domains suggesting it functions as a scaffold or adaptor protein in signaling pathways, particularly those involved in transcription and RNA processing. This gene represents a unique example of how defects in a single gene can lead to complex neurological phenotypes affecting multiple organ systems, with particularly severe impacts on auditory development and higher cognitive function.

Normal Function

Protein Structure and Domains

The SCAR20/IQCA1 protein contains several key structural features:

• IQ Motifs: Calcium-independent calmodulin-binding motifs that mediate protein-protein interactions
• Coiled-coil Regions: Involved in protein oligomerization and complex formation
• Nuclear Localization Signals (NLS): Target the protein to the nucleus
• Domain Architecture: The N-terminal region contains the IQ motifs, while the C-terminal portion includes regions for nuclear targeting and protein interactions

Subcellular Localization

SCAR20 shows specific subcellular distribution:

• Nucleus: Predominantly nuclear localization, particularly in the nucleolus
• Nucleolus: Enriched in the nucleolus, suggesting a role in ribosome biogenesis
• Cytoplasm: Lower levels in the cytoplasm, potentially representing a pool for nuclear import

Molecular Functions

SCAR20 participates in several cellular processes:

Brain Expression and Function

Regional Distribution

SCAR20 is expressed throughout the brain with highest levels in regions associated with hearing and cognition:

• Cerebral Cortex: High expression in pyramidal neurons across all cortical layers
• Hippocampus: Strong expression in CA1-CA3 pyramidal cells and dentate gyrus granule cells
• Cerebellum: Moderate expression in Purkinje cells
• Brainstem: Expression in auditory brainstem nuclei, including the cochlear nuclei
• Inner Ear: Expression in the developing inner ear, particularly in the organ of Corti

Role in Neurodevelopment

During development, SCAR20 appears to be essential for:

The multiple brain regions affected explain the global developmental delay and intellectual disability observed in patients.

Disease Associations

SCAR20 Syndrome (Autosomal Recessive Hearing Loss with Developmental Delay)

The primary disease associated with SCAR20 is a autosomal recessive disorder characterized by:

Core Features:

• Profound Sensorineural Hearing Loss: Present at birth, bilateral, profound in severity
• Global Developmental Delay: Significant delays in motor and cognitive milestones
• Intellectual Disability: Moderate to severe ID in most patients
• Facial Dysmorphism: Characteristic facial features including:
• Deep-set eyes
• Broad nasal bridge
• Small ears
• Micrognathia
• Coarse facial features

• Speech delay (absent or severely delayed speech)
• Hypotonia
• Growth retardation
• Seizures (in some patients)
• Behavioral issues (autism-like features in some)

Molecular Pathogenesis

The mechanism by which SCAR20 mutations cause disease:

Comparison to Coffin-Lowry Syndrome

Although SCAR20 was initially thought to relate to Coffin-Lowry syndrome (which is X-linked and caused by RPS6KA3 mutations), SCAR20 represents a distinct clinical entity with autosomal recessive inheritance. Both conditions share some features including developmental delay and facial dysmorphism, but the profound hearing loss in SCAR20 is distinctive.

Genetic Variants

Pathogenic Variants

| Variant Type | Example | Effect | Frequency |
|--------------|---------|--------|-----------|
| Nonsense | p.R412* | Truncation | Multiple families |
| Frameshift | c.1174delC | Protein truncation | Several families |
| Splice | c.1650+1G>A | Exon skipping | Reported |
| Missense | p.R384C | Partial function | Rare |

Mutation Spectrum

• Homozygous variants: Most patients have two identical pathogenic alleles (consanguineous families)
• Compound heterozygous: Some patients carry two different pathogenic variants
• Founder mutations: Specific variants may be enriched in certain populations

Carrier Frequency

Given the rarity of SCAR20 syndrome, carrier frequency in the general population is very low. The disorder is primarily identified through clinical evaluation and genetic testing of affected individuals and their families.

Animal Models

Mouse Models

Iqca1 knockout mice have been developed and show:

• Hearing impairment: Significant hearing loss documented by auditory brainstem responses
• Behavioral deficits: Altered open field and contextual fear conditioning performance
• Molecular changes: Altered expression of genes involved in neuronal function
• Growth abnormalities: Some models show reduced body weight

Zebrafish Models

Zebrafish morpholino knockdowns demonstrate:

• Developmental defects in the inner ear
• Motor coordination abnormalities
• Developmental delay

Model Insights

Animal studies confirm the essential role of SCAR20/IQCA1 in hearing and neurological function, providing platforms for therapeutic intervention studies.

Research Findings

Key Publications

Research Directions

• Understanding the molecular function of SCAR20 in the nucleus
• Defining the signaling pathways in which SCAR20 participates
• Developing mouse models that better recapitulate the human phenotype
• Exploring therapeutic approaches including gene therapy

Interaction Network

SCAR20 interacts with multiple cellular pathways:

Diagnostic Considerations

Genetic Testing

• Targeted panels: Hearing loss and developmental delay gene panels
• Whole exome sequencing: Often identifies SCAR20 variants
• Whole genome sequencing: May detect structural variants

Differential Diagnosis

SCAR20 should be distinguished from:

• Other forms of autosomal recessive hearing loss
• Coffin-Lowry syndrome (X-linked)
• Other causes of developmental delay with hearing loss
• Usher syndrome (hearing loss plus retinitis pigmentosa)

Clinical Management

Management includes:

• Early hearing intervention (cochlear implantation when appropriate)
• Developmental support services
• Speech and language therapy
• Regular developmental monitoring
• Genetic counseling for families

See Also

• [Genes Directory](/genes/)
• [Proteins Directory](/proteins/)
• [Intellectual disability](/diseases/intellectual-disability)
• [Sensorineural hearing loss](/diseases/sensorineural-hearing-loss)
• [Neurodevelopmental disorders](/diseases/neurodevelopmental-disorders)
• [Ribosomal biogenesis](/mechanisms/ribosomal-biogenesis)
• [Transcriptional regulation](/mechanisms/transcriptional-regulation)

External Links

• [NCBI Gene: SCAR20](https://www.ncbi.nlm.nih.gov/gene/65250)
• [OMIM: 616151](https://www.omim.org/entry/616151)
• [Ensembl: ENSG00000165704](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165704)
• [UniProt: Q96MC7](https://www.uniprot.org/uniprotkb/Q96MC7/entry)
• [ClinVar: SCAR20 variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=SCAR20)

References